05/22/2026
Fluoroquinolones in Animals: A Toxicological Problem That Should Not Be Ignored
This article is dedicated to my special friend, Teri Koko.
Fluoroquinolones are not only human antibiotics. They are also used in veterinary medicine, including in food-producing animals and companion animals. In the United States, FDA materials confirm that two fluoroquinolones, danofloxacin and enrofloxacin, are approved for specific use in food-producing animals, mainly cattle and swine, while extra-label fluoroquinolone use in food-producing animals is prohibited because of public-health concerns, including antimicrobial resistance [1]. The FDA also withdrew approval for enrofloxacin use in poultry after concluding that fluoroquinolone use in poultry contributed to fluoroquinolone-resistant Campylobacter, that resistant organisms could transfer to humans, and that such infections created a human-health hazard [2].
This means the issue is not theoretical. Fluoroquinolones have been used across the animal world: cattle, pigs, poultry historically, dogs, cats, horses, aquaculture systems, and other species depending on national regulations. The problem is that the same chemical class that can damage tendons, cartilage, nerves, mitochondria, and cellular systems in humans also has biological activity in animals. The exact risk is not identical across species, because animals differ in metabolism, transporters, detoxification capacity, microbiome structure, mitochondrial reserve, growth rate, age, and tissue exposure. But it would be scientifically weak to assume that animals are automatically protected simply because they are animals.
The official human safety record already shows that systemic fluoroquinolones can cause serious, disabling, and potentially permanent adverse effects involving tendons, muscles, joints, nerves, and the central nervous system [3]. EMA similarly states that these drugs can cause long-lasting, disabling, and potentially irreversible adverse reactions affecting multiple body systems, including musculoskeletal, nervous, psychiatric, and sensory systems [4]. These warnings are for humans, but the biological mechanisms behind toxicity — oxidative stress, mitochondrial injury, magnesium chelation, collagen disruption, neuroexcitation, and topoisomerase-related effects — are not uniquely human processes. They exist across mammalian biology.
In veterinary medicine, the Merck Veterinary Manual states directly that quinolones and fluoroquinolones can cause species-specific adverse effects. In cats, enrofloxacin has been associated with acute retinal degeneration and blindness, especially at higher doses or in susceptible animals. The same veterinary source explains that retinal damage may involve accumulation of photoreactive fluoroquinolones in the retina, followed by reactive oxygen species formation and tissue damage [5]. A retrospective clinical study of cats receiving systemic enrofloxacin reported acute blindness, diffuse retinal degeneration, loss of photoreceptor layers, and persistent or progressive retinal injury in some animals [6].
Cartilage toxicity is another major animal signal. Fluoroquinolone arthropathy was historically documented in juvenile dogs and other immature animals. Veterinary references warn that high or prolonged quinolone exposure in growing dogs and foals can produce cartilaginous erosions leading to permanent lameness, and that excessive use should be avoided in immature animals [5]. Published studies and reviews describe cartilage blistering, fissuring, erosion, and chondrocyte injury in juvenile animal models [7]. This is very important because farm animals are often young, rapidly growing, metabolically active organisms. A toxic insult to cartilage, growth plates, tendons, or connective tissue during a growth phase may have consequences different from the same exposure in a fully mature adult animal.
The mitochondrial question is probably one of the most important. The Merck Veterinary Manual now acknowledges “mitotoxicity” as an emerging toxicity associated with fluoroquinolones, including possible damage to mitochondrial topoisomerase or other mitochondrial structures, with delayed effects that may not appear immediately after treatment [5]. Experimental work has shown that bactericidal antibiotics, including quinolones, can induce mitochondrial dysfunction and oxidative stress in mammalian cells [8]. Ciprofloxacin has also been shown to impair mitochondrial DNA replication initiation through effects on mitochondrial topoisomerase 2β, resulting in disrupted mitochondrial transcription and replication initiation, mtDNA depletion, and impaired cellular proliferation or differentiation [9].
This matters for animals because mitochondria are central to muscle performance, fertility, immune response, neurological stability, growth, and detoxification. A dairy cow, racehorse, broiler chicken, breeding sow, working dog, or young foal depends on mitochondrial reserve. If fluoroquinolones reduce mitochondrial resilience, increase oxidative stress, or disturb mtDNA maintenance, the consequences could appear as poor growth, weakness, exercise intolerance, tendon or ligament vulnerability, reproductive problems, immune dysfunction, delayed recovery after infection, or unexplained decline. Not every animal will show these problems, and not every exposure will produce visible injury, but the mechanistic risk is biologically plausible.
DNA-related effects are also central to the discussion. Fluoroquinolones were designed to interfere with bacterial DNA gyrase and topoisomerase IV, but research has also raised questions about effects on mammalian topoisomerases, mitochondrial DNA topology, oxidative DNA damage, and DNA-associated stress responses [9,10]. Older mammalian-cell work reported delayed cytotoxicity and mitochondrial DNA cleavage after ciprofloxacin exposure [11]. This does not prove that every treated animal develops stable fluoroquinolone-DNA adducts, but it does support the need to investigate DNA damage, mtDNA effects, and persistent molecular injury more seriously in both human and veterinary contexts.
Drug interactions make the risk more complex. Veterinary references state that fluoroquinolones interact with antacids, sucralfate, and drugs containing multivalent cations, which can reduce gastrointestinal absorption. They also state that quinolones inhibit methylxanthine metabolism, especially theophylline, caffeine, and theobromine, which can raise methylxanthine levels and lead to central nervous system and cardiac toxicity [5]. The same source notes that quinolones can be neurotoxic and that convulsions can occur at high doses because of GABA-receptor antagonism [5]. In practical terms, an animal exposed to fluoroquinolones together with theophylline-like compounds, NSAIDs, steroids, high mineral loads, renal impairment, dehydration, or other stressors may not have the same risk profile as a healthy animal receiving a clean, isolated dose.
Corticosteroids are especially important. EMA warns that fluoroquinolones should be used with special caution in patients at higher tendon-injury risk and that combined use with corticosteroids increases this risk and should be avoided [4]. This human warning has direct conceptual relevance to veterinary medicine because corticosteroids are widely used in animals for inflammation, allergies, respiratory disease, immune conditions, and pain. When a drug class already has known connective-tissue toxicity, adding corticosteroids may reduce repair capacity, alter collagen metabolism, and increase the chance that tendon, cartilage, or ligament damage becomes clinically visible.
There is also a food-chain issue. Antibiotic residues can remain in animal-origin foods such as meat, milk, eggs, honey, and fish when withdrawal periods are not followed, when regulations are weak, or when veterinary drugs are misused [12]. Reviews on livestock antibiotic residues describe residues across multiple animal-derived food categories and emphasize public-health concerns, including antimicrobial resistance and possible toxicological exposure [12,13]. Fluoroquinolones are particularly concerning because they are considered medically important antimicrobials and because even low-level environmental or dietary residues can create selective pressure on bacteria.
The environmental route is another layer. Fluoroquinolones can enter manure, soil, wastewater, surface water, aquaculture systems, and sediments. Reviews describe fluoroquinolone contamination in water bodies and toxicity risks to freshwater organisms, including non-target aquatic species [14,15]. Manure from treated animals can carry antibiotic residues, resistant bacteria, and antibiotic-resistance genes into agricultural soil, where they may affect soil microbiota and spread resistance through environmental networks [16]. This means the toxicology is not limited to the treated animal. It can move outward into ecosystems, food production, microbial ecology, and human exposure.
The antimicrobial-resistance consequence may be the easiest to prove publicly, but it is not the only concern. The FDA poultry withdrawal decision shows that animal fluoroquinolone use can affect human bacterial resistance patterns [2]. WHO and other public-health bodies classify quinolones and fluoroquinolones as highly important or critically important antimicrobials for human medicine, meaning their agricultural use must be controlled with special caution [17]. Resistance is therefore not only a laboratory phenomenon. It can become a clinical failure: an infection that once responded to ciprofloxacin or levofloxacin may no longer respond because resistant bacteria were selected somewhere in the animal-food-environment chain.
The deeper issue is that veterinary fluoroquinolone safety is often discussed mainly through residue limits and antimicrobial resistance, while cellular toxicity is treated as secondary. That is not sufficient anymore. We should ask whether treated animals develop mitochondrial dysfunction, connective-tissue fragility, retinal damage, neurological hypersensitivity, reproductive injury, altered immune response, microbiome disruption, oxidative stress, and persistent DNA-related changes. These questions do not require exaggeration. They require proper research.
The right scientific position is cautious but firm: we cannot claim that every fluoroquinolone-treated animal is permanently damaged. We also cannot claim that legally approved use always means biologically harmless use. The evidence already shows species-specific toxicity, juvenile cartilage risk, cat retinal toxicity, mitochondrial mechanisms, drug interactions, environmental persistence, food-residue concerns, and antimicrobial-resistance consequences. That is enough to justify stricter veterinary stewardship, better post-treatment monitoring, residue surveillance, and independent mechanistic studies in animals.
If society is willing to ask whether fluoroquinolones can cause long-lasting multi-system injury in humans, it must also ask what happens when similar molecules are used in animals that become food, breeding stock, companions, workers, or environmental exposure sources. The animal question is not separate from the human question. It is part of the same toxicological map.
____________________________________________________________
✅Disclaimer: This article is for educational and research discussion only. It is not medical or veterinary advice, does not diagnose or treat any animal or human condition, and should not replace individualized judgment by a licensed physician, veterinarian, toxicologist, or qualified laboratory scientist. The purpose is to raise scientifically reasonable questions about fluoroquinolone exposure, animal health, food safety, environmental contamination, antimicrobial resistance, and the need for independent research.
💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: https://fq100.org/drug-list
Find support and resources on our sites:
🌐 Website & Resources: https://fq100.org/
▶️ YouTube: https://www.youtube.com/
🔵 Facebook: https://www.facebook.com/fqtoxicitystudy/
🐦 X/Twitter: https://twitter.com/FQ_100
Post graphic generated and text edited with assistance from ChatGPT.
References
[1] FDA Center for Veterinary Medicine. “Extralabel Use and Antimicrobials.” FDA states that danofloxacin and enrofloxacin are approved for specific food-producing animal uses in the U.S., and that extra-label fluoroquinolone use in food-producing animals is prohibited.
[2] FDA Center for Veterinary Medicine. “Withdrawal of Enrofloxacin for Poultry.” FDA concluded that poultry fluoroquinolone use contributed to fluoroquinolone-resistant Campylobacter and human-health risk.
[3] FDA. “FDA approves safety labeling changes for fluoroquinolones.” The FDA described disabling and potentially permanent serious side effects involving tendons, muscles, joints, nerves, and the central nervous system.
[4] European Medicines Agency. “Fluoroquinolone antibiotics: reminder of measures to reduce the risk of long-lasting, disabling and potentially irreversible side effects.” EMA describes restrictions, multi-system adverse reactions, tendon injury risk, and increased risk with corticosteroids.
[5] Merck Veterinary Manual. “Quinolones, Including Fluoroquinolones, for Use in Animals.” Includes veterinary use, species approvals, adverse effects, retinal toxicity in cats, cartilage damage in immature animals, mitotoxicity, and drug interactions.
[6] Gelatt KN et al. “Enrofloxacin-associated retinal degeneration in cats.” Veterinary Ophthalmology, 2001. PubMed abstract reports acute blindness and diffuse retinal degeneration after systemic enrofloxacin in cats.
[7] Sansone JM et al. “The Effect of Fluoroquinolone Antibiotics on Growing Cartilage in the Lamb Model.” Journal of Children’s Orthopaedics, 2009. Review context includes quinolone chondrotoxicity, cartilage blistering, fissuring, erosion, and arthropathy.
[8] Kalghatgi S et al. “Bactericidal Antibiotics Induce Mitochondrial Dysfunction and Oxidative Damage in Mammalian Cells.” Science Translational Medicine, 2013.
[9] Hangas A et al. “Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2.” Nucleic Acids Research, 2018.
[10] Aldred KJ et al. “Examining the Impact of Antimicrobial Fluoroquinolones on Human DNA Topoisomerase II.” ACS Omega, 2019. The authors discuss possible roles of human topoisomerase II isoforms in fluoroquinolone toxicity while noting that other targets are likely involved.
[11] Lawrence JW et al. “Delayed Cytotoxicity and Cleavage of Mitochondrial DNA in Ciprofloxacin-Treated Mammalian Cells.” Molecular Pharmacology, 1996.
[12] Mesfin YM et al. “Veterinary Drug Residues in Food Products of Animal Origin.” 2024 review discussing drug residues in milk, eggs, honey, meat, and other animal-origin foods.
[13] Ghimpețeanu OM et al. “Antibiotic Use in Livestock and Residues in Food—A Public Health Threat.” 2022 review describing antibiotic residues across meat, milk, eggs, honey, and other food groups.
[14] Shen M et al. “Occurrence, Bioaccumulation, Metabolism and Ecotoxicity of Fluoroquinolones in Water Bodies.” 2023 review.
[15] Pauletto M et al. “A Review on Fluoroquinolones’ Toxicity to Freshwater Organisms and a Risk Assessment.” 2024 review.
[16] Tian M et al. “Pollution by Antibiotics and Antimicrobial Resistance in Livestock and Poultry Manure.” 2021 review.
[17] World Health Organization. “WHO List of Medically Important Antimicrobials: a risk management tool for mitigating antimicrobial resistance due to non-human use.” 2024 update.
